目的 探讨乙肝舒康胶囊联合恩替卡韦和复方甘草酸苷治疗慢性重症乙型肝炎的临床疗效。方法 选取2015年1月-2016年1月在延安大学附属医院接受治疗的慢性重症乙型肝炎患者96例，按照治疗方法的差别分成对照组和治疗组，每组各48例。对照组口服恩替卡韦片，1片/次，1次/d；并口服复方甘草酸苷片，3片/次，3次/d。治疗组在对照组基础上口服乙肝舒康胶囊，4粒/次，3次/d。两组患者均治疗16周。观察两组的临床疗效，比较两组的肝功能和乙肝病毒脱氧核糖核酸（HBV-DNA）水平。结果 治疗后，对照组和治疗组的总有效率分别为83.33%、95.83%，两组比较差异有统计学意义（P<0.05）。治疗后，两组丙氨酸转氨酶（ALT）、天氨酸转氨酶（AST）、总胆红素（TBIL）及直接胆红素（DBIL）均明显降低，而凝血酶原活动度（PTA）显著升高，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组这些观察指标的改善程度明显优于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组HBV-DNA水平均明显降低，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组HBV-DNA水平的下降程度明显优于对照组，两组比较差异具有统计学意义（P<0.05）。结论 乙肝舒康胶囊联合恩替卡韦和复方甘草酸苷治疗慢性重症乙型肝炎具有较好的疗效，可明显降低患者血清HBV-DNA水平，改善患者肝功能，具有一定的临床推广应用价值。

Objective To investigate the clinical effect of Yigan Shukang Capsules combined with entecavir and compound glycyrrhizin in treatment of chronic severe hepatitis B. Methods Patients (86 cases) with chronic severe hepatitis B in Yan'an University Affiliated Hospital from January 2015 to January 2016 were enrolled in this study. According to the difference treatment plan, patients were divided into control and treatment groups, and each group had 48 cases. Patients in the control group were po administered with Entecavir Tablets, 1 tablet/time, once daily. And patients in the control group were also po administered with Compound Glycyrrhizin Tablets, 3 tablet/time, three times daily Patients in the treatment group were po administered with Yigan Shukang Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 16 weeks. After treatment, the clinical efficacies were evaluated, and liver function and HBV-DNA levels in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 83.33% and 95.83%, respectively, and there was difference between two groups (P<0.05). After treatment, ALT, AST, TBIL, and DBIL in two groups were significantly decreased, but PTA in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, the HBV-DNA levels in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the HBV-DNA level in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Yigan Shukang Capsules combined with entecavir and compound glycyrrhizin has clinical curative effect in treatment of chronic severe hepatitis B, and can significantly decrease serum HBV-DNA level, improve liver function, which has a certain clinical application value.